Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Kubanov (Author), A. L. Bakulev (Author), M. I. Gluzmin (Author), M. M. Kokhan (Author), L. S. Kruglova (Author), N. S. Rudneva (Author), O. Yu. Olisova (Author), E. V. Sokolovsky (Author), M. M. Khobeish (Author)
Format: Book
Published: State Scientific Center of Dermatovenereology and Cosmetology, 2019-12-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items